Correlation of fluconazole MICs with clinical outcome in cryptococcal infection

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 6, 2000, Pages 1544-1548

  Aller, A I ^a   Martin Mazuelos, E ^a   Lozano, F ^a   Gomez Mateos, J ^a   Steele Moore, L ^b   Holloway, W J ^b   Gutierrez M J ^a   Recio, F J ^a   Espinel Ingroff, A ^c  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b Christiana Care   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG EFFICACY; DRUG SENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE, MICROBIAL; FLUCONAZOLE; HUMANS; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 0034077975     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.6.1544-1548.2000     Document Type: Article

References (22)

1. Anaissie, E., R. Shawar, V. Paetznick, L. G. Ensign, Z. Witte, and M. Larocco. 1993. Two-site Comparison of broth microdilution and semisolid agar dilution methods for susceptibility testing of Cryptococcus neofomans in three Media. J. Clin. Microbiol. 31:1370-1372.
2. Armengou, A., Porcar C., Mascaró J. and García-Bragado. F. 1996. Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis. Clin. Infect. Dis. 23:1337-1338.
3. Birley, H. D. L., Johnson E. M., McDonald P., Parry C., Carey P. B. and Warnock, D. W. 1995. Azole drug resistance as a cause of clinical relapse in AIDS patients with cryptococcal meningitis. Int. J. STD AIDS. 6:353-355.
4. Casadevall, A., Spitzer E. D., Webb D. and Rinaldi. M. G. 1993. Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole. Antimicrob. Agents Chemother. 37:1383-1386.
5. Dismukes, W. E. 1988. Cryptococcal meningitis in patients with AIDS. J. Infect. Dis. 157:624-628.
6. Dismukes, W. E. 1993. Management of cryptococcosis. Clin. Infect. Dis. 17(Suppl. 2):S507-S512.
7. Espinel-Ingroff, A., C. W. Kish, T. M. Kerkering, R. A. Fromtling, K. Bartizal, J. N. Galgiani, K. Villareal, M. A. Pfaller, T. Gerarden, M. G. Rinaldi, and A. Fothergill. 1992. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility test. J. Clin. Microbiol. 30:3138-3145.
8. Franzot, S. P., and J. S. Hamdan. 1996. In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs. Antimicrob. Agents Chemother. 40:822-824.
9. Ghannoum, M. A., Ibrahim A. S., Yue Fu, Shafiq M. C., Edwards J. E. and Criddle. R. S. 1992. Susceptibility testing of Cryptococcus neoformans: a microdilution technique. J. Clin. Microbiol. 30:2881-2886.
10. Ghannoum, M. A., Rex J. H. and Galgiani. J. N. 1996. Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. J. Clin. Microbiol. 34:489-495.
11. Guinet, R., Nerson D., de Closets F., Dupouy-Camet J., Kures L., Marjollet M. and Volle. P. J. 1988. Collaborative evaluation in seven laboratories of a standardized micromethod for yeast susceptibility testing. J. Clin. Microbiol. 26:2307-2312.
12. Harrison, M. J. G., and J. C. McArthur. 1995. Opportunistic infections -fungi. In AIDS and neurology. Churchill Livingstone, Ltd. Edinburgh, United Kingdom.
13. Jessup, C. J., Pfaller M. A., Messer S. A., Zhang J., Tumberland M., Mbidde E. K. and Ghannoum. M. A. 1998. Fluconazole susceptibility testing of Cryptococcus neoformans: comparison of two broth microdilution methods and clinical correlates among isolates from Ugandan AIDS patients. J. Clin. Microbiol. 36:2874-2876.
14. Johnson, E. M., Richardson M. D. and Warnock. D. W. 1984. In vitro resistance to imidazole antifungals in Candida albicans. J. Antimicrob. Chemother. 13:547-558.
15. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
16. Paugam, A., Dupouy-Camet P., Gangneux J. P., Tourte-Schafer C. and Sicard. D. 1994. Increased fluconazole resistance of C. neoformans isolated from a patients with AIDS and recurrent meningitis. Clin. Infect. Dis. 19: 975-976.
17. Powderly, W. G., Saag M. S., Cloud G. A., Robinson P., Meyer R. D., Jacobson J. M., J. R. Graybill, A. M. Sugar, V. J. McAuliffe, S. E. Follansbee et al. 1992. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 326:793-798.
18. Powderly, W. G. 1993. Cryptococcal meningitis and AIDS. Clin. Infect. Dis. 17:837-842.
19. Powderly, W. G. 1994. Fungi. In S. Broder, T. C. Merigan, and D. Bolognes (ed.) Texbook of AIDS medicine. The Williams & Wilkins Co., Baltimore, Md.
20. Rex, J. H., M. A. Waller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
21. Sanati, H., Messer S. A., Pfaller M., Witt M., Espinel-Ingroff A. and Ghannoum. M. 1996. Multicenter evaluation of broth microdilution method for susceptibility testing of Cryptococcus neoformans against fluconazole. J. Clin. Microbiol. 34:1280-1282.
22. Witt, M. D., Lewis R. J., Larsen A., Milefchik E. N., Leal M. A., Haubrich R H., J. A. Richie, J. E. Edwards, Jr., and M. A. Ghannoum. 1996. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clin. Infect. Dis. 22:322-328.